obesity drug news today glp-1 september 29 2025 The Access Gap: Mapping Who Can Actually Afford America's Miracle Weight-Loss Drugs Outlook for obesity in 2025:

Tirzepatide and other incretin-based therapies do not directly interact with thyroid hormone replacement at a pharmacokinetic level

This means your employer - not BCBS - decides whether drugs like Foundayo are covered

Resources We Trust Mayo Clinic: Psoriasis Cleveland Clinic: Rheumatoid Arthritis National Institutes of Health: Autoimmune Diseases American Academy of Dermatology Association: Psoriasis: Causes Arthritis Foundation: Understanding Rheumatoid Arthritis Flares Martin A et al

Retrieved from Jensterle, M., Rizzo, M., Haluzk, M., et al

The team studied a GLP-1 receptor agonist called Exendin-4-Phe (Ex-Phe-1), a molecule created by researchers in the United Kingdom by substituting an amino acid in the standard GLP-1 agonist Exendin-4

Baird G